Neurofilaments in the diagnosis of motoneuron diseases: A prospective study on 455 patients

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 87, Issue 1, 2016, Pages 12-20

  Steinacker, Petra ^a   Feneberg, Emily ^a   Weishaupt, Jochen ^a   Brettschneider, Johannes ^a   Tumani, Hayrettin ^a   Andersen, Peter M ^b   Arnim, Christine A F Von ^a   Böhm, Sarah ^a   Kassubek, Jan ^a   Kubisch, Christian ^c,d   Lulé, Dorothée ^a   Müller, Hans Peter ^a   Muche, Rainer ^c   Pinkhardt, Elmar ^a   Oeckl, Patrick ^a   Rosenbohm, Angela ^a   Anderl Straub, Sarah ^a   Volk, Alexander E ^c,d   Weydt, Patrick ^a   Ludolph, Albert C ^a   Otto, Markus ^a   more..

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b UMEÅ UNIVERSITY   (Sweden)

^c UNIVERSITY OF ULM   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROFILAMENT HEAVY CHAIN; NEUROFILAMENT LIGHT CHAIN; NEUROFILAMENT PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; DNA; MAPT PROTEIN, HUMAN;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CEREBROSPINAL FLUID; COHORT ANALYSIS; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DISEASE DURATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIMARY LATERAL SCLEROSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN PHOSPHORYLATION; SENSITIVITY AND SPECIFICITY; ADOLESCENT; GENETICS; INTERMEDIATE FILAMENT; MIDDLE AGED; MOTOR NEURON DISEASE; NEUROLOGIC EXAMINATION; PATHOLOGY; PROGNOSIS; REPRODUCIBILITY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMYOTROPHIC LATERAL SCLEROSIS; BIOMARKERS; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; DNA; FEMALE; HUMANS; INTERMEDIATE FILAMENTS; MALE; MIDDLE AGED; MOTOR NEURON DISEASE; NEUROFILAMENT PROTEINS; NEUROLOGIC EXAMINATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; TAU PROTEINS; YOUNG ADULT;

EID: 84956632857     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2015-311387     Document Type: Article

References (40)

1. Chio A, Logroscino G, Traynor BJ, et al. Global epidemiology of amyotrophic lateral sclerosis: A systematic review of the published literature. Neuroepidemiology 2013;41:118-30.
2. Traynor BJ, Codd MB, Corr B, et al. Amyotrophic lateral sclerosis mimic syndromes: A population-based study. Arch Neurol 2000;57:109-13.
3. Turner MR, Talbot K. Mimics and chameleons in motor neurone disease. Pract Neurol 2013;13:153-64.
4. Turner MR, Benatar M. Ensuring continued progress in biomarkers for amyotrophic lateral sclerosis. Muscle Nerve 2015;51:14-18.
5. Lehnert S, Costa J, de Carvalho M, et al. Multicentre quality control evaluation of different biomarker candidates for amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2014;15:344-50.
6. Rosengren LE, Karlsson JE, Karlsson JO, et al. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem 1996;67:2013-18.
7. Ganesalingam J, An J, Shaw CE, et al. Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS. J Neurochem 2011;117:528-37.
8. Reijn TS, Abdo WF, Schelhaas HJ, et al. CSF neurofilament protein analysis in the differential diagnosis of ALS. J Neurol 2009;256:615-19.
9. Tortelli R, Ruggieri M, Cortese R, et al. Elevated cerebrospinal fluid neurofilament light levels in patients with amyotrophic lateral sclerosis: A possible marker of disease severity and progression. Eur J Neurol 2012;19:1561-7.
10. Boylan KB, Glass JD, Crook JE, et al. Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2013;84:467-72.
11. Brettschneider J, Petzold A, Sussmuth SD, et al. Axonal damage markers in cerebrospinal fluid are increased in ALS. Neurology 2006;66:852-6.
12. Gaiottino J, Norgren N, Dobson R, et al. Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS ONE 2013;8:e75091.
13. Ganesalingam J, An J, Bowser R, et al. pNfH is a promising biomarker for ALS. Amyotroph Lateral Scler Frontotemporal Degener 2013;14:146-9.
14. Puentes F, Topping J, Kuhle J, et al. Immune reactivity to neurofilament proteins in the clinical staging of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2014;85:274-8.
15. Tortelli R, Copetti M, Ruggieri M, et al. Cerebrospinal fluid neurofilament light chain levels: marker of progression to generalized amyotrophic lateral sclerosis. Eur J Neurol 2014;22:215-8.
16. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:263-9.
17. Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-4.
18. Brooks BR, Miller RG, Swash M, et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2000;1:293-9.
19. De Jesus-Hernandez M, Mackenzie IR, Boeve BF, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011;72:245-56.
20. Hubers A, Marroquin N, Schmoll B, et al. Polymerase chain reaction and Southern blot-based analysis of the C9orf72 hexanucleotide repeat in different motor neuron diseases. Neurobiol Aging 2014;35:1214.e1-6.
21. Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: A revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci 1999;169:13-21.
22. Lule D, Burkhardt C, Abdulla S, et al. The Edinburgh cognitive and behavioural amyotrophic lateral sclerosis screen: A cross-sectional comparison of established screening tools in a German-Swiss population. Amyotroph Lateral Scler Frontotemporal Degener 2015:16:16-23.
23. Osborne RA, Sekhon R, Johnston W, et al. Screening for frontal lobe and general cognitive impairment in patients with amyotrophic lateral sclerosis. J Neurol Sci 2014;336:191-6.
24. Welsh KA, Butters N, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part V. A normative study of the neuropsychological battery. Neurology 1994;44:609-14.
25. Turner JA, Mejino JL, Brinkley JF, et al. Application of neuroanatomical ontologies for neuroimaging data annotation. Front Neuroinform 2010 Jun 10;4 doi:10.3389/fninf.2010.00010.
26. Kassubek J, Muller HP, Del Tredici K, et al. Diffusion tensor imaging analysis of sequential spreading of disease in amyotrophic lateral sclerosis confirms patterns of TDP-43 pathology. Brain 2014;137(Pt6):1733-40.
27. Jesse S, Brettschneider J, Sussmuth SD, et al. Summary of cerebrospinal fluid routine parameters in neurodegenerative diseases. J Neurol 2011;258:1034-41.
28. Otto M, Wiltfang J, Cepek L, et al. Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 2002;58: 192-7.
29. Otto M, Bowser R, Turner M, et al. Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. Amyotroph Lateral Scler 2012;13:1-10.
30. Zetterberg H, Jacobsson J, Rosengren L, et al. Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: impact of SOD1 genotype. Eur J Neurol 2007;14:1329-33.
31. Koel-Simmelink MJ, Vennegoor A, Killestein J, et al. The impact of pre-analytical variables on the stability of neurofilament proteins in CSF, determined by a novel validated SinglePlex Luminex assay and ELISA. J Immunol Methods 2014;402:43-9.
32. Lu CH, MacDonald-Wallis C, Gray E, et al. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. Neurology 2015;84:2247-57.
33. Petzold A, Keir G, Green AJ, et al. A specific ELISA for measuring neurofilament heavy chain phosphoforms. J Immunol Methods 2003;278:179-90.
34. Grossman M, Elman L, McCluskey L, et al. Phosphorylated tau as a candidate biomarker for amyotrophic lateral sclerosis. JAMA Neurol 2014;71:442-8.
35. Sussmuth SD, Sperfeld AD, Hinz A, et al. CSF glial markers correlate with survival in amyotrophic lateral sclerosis. Neurology 2010;74:982-7.
36. Jimenez-Jimenez FJ, Hernanz A, Medina-Acebron S, et al. Tau protein concentrations in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neurol Scand 2005;111:114-17.
37. Menke RAL, Gray E, Lu C-H, et al. CSF neurofilament light chain reflects corticospinal tract degeneration in ALS. Ann Clin Transl Neurol 2015. in press.
38. Yuan A, Rao MV, Veeranna, et al Neurofilaments at a glance. J Cell Sci 2012;125:3257-63.
39. Binukumar BK, Shukla V, Amin ND, et al. Topographic regulation of neuronal intermediate filaments by phosphorylation, role of peptidyl-prolyl isomerase 1: significance in neurodegeneration. Histochem Cell Biol 2013;140: 23-32.
40. Mattsson N, Zetterberg H, Hansson O, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 2009;302: 385-93.